Ceapro Announces Acceptance of Abstract for Presentation at the 2019 American College of Sports Medicine Annual Meeting
EDMONTON, Alberta, March 27, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the Annual World Congress of the American College of Sports Medicine (ACSM) being held at the Orange County Convention Center and Rosen Hotel in Orlando, Florida, May 28-June 1, 2019.
Tianou Zhang MD, PhD, Assistant Professor at the Department of Kinesiology, Health and Nutrition of the University of Texas at San Antonio will present the abstract entitled, “Immunoregulatory Effects of Oat Avenanthramides during Downhill Running in Young Men and Women.” The abstract will be published in Medicine and Science in Sports and Exercise, Volume 51:5 Supplement.
The details of the Company’s poster presentation are as follows:
|Session Title:||Immunology III|
|Session Date:||Friday, May 31, 2019|
|Presentation Time:||11:00 am – 12:30 pm ET|
|Presenter:||Tianou Zhang MD, PhD|
|Abstract #8055:||Immunoregulatory Effects of Oat Avenanthramides during Downhill Running in Young Men and Women|
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
Gilles R. Gagnon, M.Sc., MBA
President & CEO
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Released March 27, 2019